Serenex

Rationalisation of proteomics analysis, screening technologies, instrumentation, software

Serenex was founded in 2001.

Richard Kent (CEO)
Ian A. W. Howes (CFO)

Paul A. Howard (Chairman)
Richard S. Kent
Devin Hosea
Thomas A. Krake
Garheng Kong
Elizabeth H. S. Wyatt
Barrie Hesp

Timothy Haystead (Chairman)
Eric Gordon
Lee Graves
Timothy Macdonald
William Pearson
Chi-Huey Wong

323 Foster Street
Durham, NC 27701
USA
Phone: +1-919-281-6001
Fax: +1-919-281-6050

The Functional Proteome Fractionation™ Technology uses naturally occurring bioactive molecules as capture ligands, which are able to capture functionally related sub-proteomes of known therapeutic significance.
Proteome Mining™ Technology is for the rapid identification of valuable therapeutic candidates, for finding/eliminating potential side effects/toxicity in drug candidates, for example.